Form 8-K - Current report:
SEC Accession No. 0001193125-24-257915
Filing Date
2024-11-14
Accepted
2024-11-14 06:05:56
Documents
17
Period of Report
2024-11-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d912933d8k.htm   iXBRL 8-K 29620
2 EX-1.1 d912933dex11.htm EX-1.1 284273
3 EX-4.1 d912933dex41.htm EX-4.1 66569
4 EX-5.1 d912933dex51.htm EX-5.1 8785
8 GRAPHIC g912933g1114051317439.jpg GRAPHIC 2675
  Complete submission text file 0001193125-24-257915.txt   615564

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA etnb-20241112.xsd EX-101.SCH 2846
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE etnb-20241112_lab.xml EX-101.LAB 17996
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE etnb-20241112_pre.xml EX-101.PRE 11259
19 EXTRACTED XBRL INSTANCE DOCUMENT d912933d8k_htm.xml XML 3627
Mailing Address 142 SANSOME STREET SECOND FLOOR SAN FRANCISCO CA 94104
Business Address 142 SANSOME STREET SECOND FLOOR SAN FRANCISCO CA 94104 (415) 432-9270
89bio, Inc. (Filer) CIK: 0001785173 (see all company filings)

EIN.: 831114349 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39122 | Film No.: 241456784
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)